stock markets

approval

260,000 people

1,250 studies

effective drugs

vaccines

Subscribe to KHN’s free Weekly Edition newsletter.

announcing the results

recover more quickly

already announced

rheumatoid arthritis

stem cells

T cells

synthetic antibodies

existing medications

antivirals for influenza

arthritis drugs

estrogen patches

antacids

hot flashes

The Lancet

failed when tested against Ebola

favipiravir,

heavily touted by President Donald Trump

approved forms of those drugs for emergency use

dangerous heart rhythm problems.

New England Journal of Medicine

neutralize

will become immune

1918 flu pandemic

to improve survival

intravenous immunoglobulin

weakened immune systems fight off infections.

Dr. Anar Yukhayev, pictured on March 24, was hospitalized at Long Island Jewish Medical Center for COVID-19. He agreed to join a clinical trial of Kevzara, an immune suppressant.(Courtesy of Dr. Anar Yukhayev)

Actemra

anakinra

siltuximab

Kevzara

Dr. Anar Yukhayev,

Dr. Anar Yukhayev donates plasma on April 18, after making a full recovery from COVID-19.(Courtesy of Dr. Anar Yukhayev)

Telemundo

details

[email protected]

@LizSzabo

Health Industry Pharmaceuticals Public Health

COVID-19 Vaccines

Source:  from Kaiser Health News is a nonprofit news service covering health issues. It is an editorially independent program of the Kaiser Family Foundation, which is not affiliated with Kaiser Permanente. More Read More